Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

DNA repair systems in rhabdomyosarcoma.

Tsioli PG, Patsouris ES, Giaginis C, Theocharis SE.

Histol Histopathol. 2013 Aug;28(8):971-84. doi: 10.14670/HH-28.971. Epub 2013 Mar 21. Review.

PMID:
23516236
2.

Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.

Ragazzini P, Gamberi G, Pazzaglia L, Serra M, Magagnoli G, Ponticelli F, Ferrari C, Ghinelli C, Alberghini M, Bertoni F, Picci P, Benassi MS.

Histol Histopathol. 2004 Apr;19(2):401-11. doi: 10.14670/HH-19.401. Erratum in: Histol Histopathol. 2004 Jul;19(3):1013.

PMID:
15024701
3.

Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.

Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K, Shipley J, Hahn H, Fulda S.

Oncogene. 2010 Dec 2;29(48):6323-30. doi: 10.1038/onc.2010.368. Epub 2010 Sep 6.

PMID:
20818440
4.

Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.

Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG.

Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Epub 2011 May 25.

5.

The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.

Basma H, Ghayad SE, Rammal G, Mancinelli A, Harajly M, Ghamloush F, Dweik L, El-Eit R, Zalzali H, Rabeh W, Pisano C, Darwiche N, Saab R.

Int J Cancer. 2016 Mar 15;138(6):1528-37. doi: 10.1002/ijc.29886. Epub 2015 Oct 22.

6.

PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.

Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J.

Br J Cancer. 2007 Sep 17;97(6):785-91.

7.

Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.

Szuhai K, de Jong D, Leung WY, Fletcher CD, Hogendoorn PC.

J Pathol. 2014 Feb;232(3):300-7. doi: 10.1002/path.4307.

PMID:
24272621
8.

Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.

de Souza RR, Oliveira ID, Caran EM, Alves MT, Abib S, Toledo SR.

Growth Horm IGF Res. 2012 Dec;22(6):245-9. doi: 10.1016/j.ghir.2012.07.003. Epub 2012 Oct 16.

PMID:
23079386
9.

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ.

Am J Pathol. 2009 Feb;174(2):550-64. doi: 10.2353/ajpath.2009.080631. Epub 2009 Jan 15.

10.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

12.

TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.

Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O'Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF.

Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2.

13.

Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.

Laé M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG, Ladanyi M.

J Pathol. 2007 Jun;212(2):143-51.

PMID:
17471488
14.

Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.

Seki M, Nishimura R, Yoshida K, Shimamura T, Shiraishi Y, Sato Y, Kato M, Chiba K, Tanaka H, Hoshino N, Nagae G, Shiozawa Y, Okuno Y, Hosoi H, Tanaka Y, Okita H, Miyachi M, Souzaki R, Taguchi T, Koh K, Hanada R, Kato K, Nomura Y, Akiyama M, Oka A, Igarashi T, Miyano S, Aburatani H, Hayashi Y, Ogawa S, Takita J.

Nat Commun. 2015 Jul 3;6:7557. doi: 10.1038/ncomms8557.

15.

Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.

Zin A, Bertorelle R, Dall'Igna P, Manzitti C, Gambini C, Bisogno G, Rosolen A, Alaggio R.

Am J Surg Pathol. 2014 Feb;38(2):273-8. doi: 10.1097/PAS.0000000000000105.

PMID:
24418861
16.

Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.

Nishimura R, Takita J, Sato-Otsubo A, Kato M, Koh K, Hanada R, Tanaka Y, Kato K, Maeda D, Fukayama M, Sanada M, Hayashi Y, Ogawa S.

Cancer Sci. 2013 Jul;104(7):856-64. doi: 10.1111/cas.12173. Epub 2013 May 23.

17.

Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.

Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR.

Pediatr Dev Pathol. 2009 Mar-Apr;12(2):127-35. doi: 10.2350/08-05-0477.1. Epub 2008 Sep 12.

PMID:
18788888
18.

New insights into signalling-pathway alterations in rhabdomyosarcoma.

Zhu B, Davie JK.

Br J Cancer. 2015 Jan 20;112(2):227-31. doi: 10.1038/bjc.2014.471. Epub 2014 Sep 11. Review.

19.

Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.

Walther C, Mayrhofer M, Nilsson J, Hofvander J, Jonson T, Mandahl N, Øra I, Gisselsson D, Mertens F.

Genes Chromosomes Cancer. 2016 Jan;55(1):3-15. doi: 10.1002/gcc.22285. Epub 2015 Oct 20.

PMID:
26482321
20.

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Ahn EH, Mercado GE, Laé M, Ladanyi M.

Oncol Rep. 2013 Aug;30(2):968-78. doi: 10.3892/or.2013.2513. Epub 2013 Jun 3.

Supplemental Content

Support Center